Prevalence and Variability of Internal Mammary Artery Graft Use in Contemporary Multivessel Coronary Artery Bypass Graft Surgery: Analysis of the Society of Thoracic Surgeons National Cardiac Database
Use of an internal mammary artery (IMA) is a well-recognized, nationally endorsed quality indicator for evaluating the process of operative care for coronary artery bypass graft surgery. This study assesses the current status of IMA use, the association of hospital volume and IMA use, and disparities in IMA use by patient gender and race and by region of hospital location. These findings highlight the variability of IMA graft use by hospitals, the infrequent use of bilateral IMA, and the disparity of IMA use by gender and race. Frequency of IMA use in coronary artery bypass graft surgery is increasing; however, many patients still do not receive the benefits of IMA grafts, and some hospitals have a very low IMA use rate. Hospital volume is not associated with IMA use in coronary artery bypass graft surgery. Analysis of this critical performance measure also reveals significant gender and race disparities. See p 935.
Cardiovascular Mortality and Exposure to Airborne Fine Particulate Matter and Cigarette Smoke: Shape of the Exposure-Response Relationship
Active cigarette smoking is well established as a major independent cause of cardiovascular disease on the basis of extensive epidemiological, clinical, and experimental data. Compared with active cigarette smoking, passive exposure to secondhand cigarette smoke and ambient air pollution results in extremely small estimated daily doses of inhaled fine particulate and related pollutants. Yet there is substantial and growing evidence that secondhand cigarette smoke and ambient air pollution also contribute to cardiovascular disease, with risk estimates much higher than predicted on the basis of simple extrapolations of the effects of active smoking that assume a linear exposure-response function. The present study empirically explores the shape of the exposure-response relationship by integrating analyses of data from a prospective cohort mortality study of Ͼ1 million adults (collected by the American Cancer Society as part of the Cancer Prevention Study II) and exposure and risk information from comparison studies of air pollution and secondhand cigarette smoke. With the use of estimated average daily inhaled dose of fine particulate as the common exposure metric, the exposure-response relationship appears to be relatively steep at low levels of exposure. The largest marginal increases in cardiovascular risk occur at remarkably low levels of exposure. Therefore, much of the excess cardiovascular risk from active smoking occurs even at very low levels of smoking, and smaller but substantive excess risks are also associated with passive exposure to secondhand smoke and ambient air pollution. See p 941.
Emergency Hospital Admissions for Cardiovascular Diseases and Ambient Levels of Carbon Monoxide: Results for 126 United States Urban Counties, 1999 -2005
With growing traffic in many urban centers, the health impacts of traffic-related air pollution are a current public health concern. This national study of 126 US urban counties during 1999 -2005 examines whether exposure to carbon monoxide (CO) on the same day and previous few days increases risk of cardiovascular disease (CVD) hospitalizations for an older population based on Ͼ9.3 million Medicare enrollees aged Ն65 years. Our findings indicate that higher levels of CO exposure are associated with an increased risk of CVD hospitalizations on the same day for multiple causespecific CVD outcomes (ischemic heart disease, heart rhythm disturbances, heart failure, cerebrovascular disease, and total CVD admissions). Although it is not possible to fully disentangle the effects of CO and of other air pollutants produced by traffic, the association between CO and CVD hospital admissions remained after adjustment for other traffic-related pollutants: NO 2 , fine particulate matter (with aerodynamic diameter Յ2.5 m) total mass, and elemental carbon. The risk persisted even at low CO levels Ͻ1 ppm, which are well below the current US health-based regulatory standard. This study provides one of the first population-based investigations of the health effects of current low ambient CO levels and indicates that exposure to current CO levels may still pose a threat to public health, particularly for persons with CVD. It adds to other research showing that air pollution harms the health of people with CVD. See p 949.
Perceived Level of Life Enjoyment and Risks of Cardiovascular Disease Incidence and Mortality: The Japan Public Health Center-Based Study
Although relationships between negative psychological conditions and risk of cardiovascular disease incidence and mortality have been well documented, little is known about associations between positive psychological conditions and the risk of disease. Perceived level of life enjoyment, a positive psychological condition that reflects the ability to engage pleasurably with the environment, may relate to risks of cardiovascular disease. This community-based prospective study of Ϸ90 000 Japanese 40 to 69 years of age showed that lower 919
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Original Research Put Into Perspective for the Practicing Clinician Volume 120 Ⅲ Number 11 Ⅲ September 15, 2009 sense of life enjoyment was associated with higher risks of cardiovascular disease incidence and mortality. The multivariable hazard ratios of cardiovascular disease incidence for men in the low versus high perceived levels of life enjoyment group were 1.22 (95% confidence interval, 1.01 to 1.47) for stroke and 1.23 (95% confidence interval, 1.05 to 1.44) for total cardiovascular disease. As for mortality, Japanese men with low perceived level of life enjoyment showed increased risk: hazard risks of 1.75 (95% confidence interval, 1.28 to 2.38) for stroke, 1.91 (95% confidence interval, 1.30 to 2.81) for coronary heart disease, and 1.61 (95% confidence interval, 1.32 to 1.96) for total cardiovascular disease. The inverse association did not change substantially when cardiovascular deaths that occurred after the first to sixth year from baseline were excluded. For women, perceived level of life enjoyment was not associated with risks of cardiovascular disease incidence and mortality. Our findings suggest a protective role of positive psychological conditions on cardiovascular disease among middle-aged men. See p 956.
Long-Term Outcome of Drug-Eluting Stents Compared With Bare Metal Stents in ST-Segment Elevation Myocardial Infarction: Results of the Paclitaxel-or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty (PASEO) Randomized Trial
This trial provides long-term results for both paclitaxel-eluting stents and sirolimus-eluting stents compared with bare metal stents in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty. In fact, although drug-eluting stents may offer benefits in terms of repeat revascularization, they may be counterbalanced by a potential higher risk of stent thrombosis, especially among ST-segment elevation myocardial infarction patients. Follow-up angiography was not routinely performed but was performed only in cases of clinical or instrumental evidence of myocardial ischemia. Follow-up data were obtained in all patients. Although mortality was not very different across arms, competingrisks analyses were carried out with death as the competing event to avoid any influence of death on the occurrence and evaluation of the outcome of interest. Our study showed the superiority of both drug-eluting stents in terms of target lesion revascularization at 1 year (primary end point) at the long-term follow-up compared with bare metal stents and no excess risk of thrombotic complications despite a relatively short-term duration of dual antiplatelet therapy (almost all patients stopped clopidogrel 6 months after the procedure). See p 964.
Critical Role of Mast Cell Chymase in Mouse Abdominal Aortic Aneurysm Formation
Mast cells, the primary players in allergic immune responses, have also been implicated in the pathogenesis of many nonallergic human diseases, such as cancer, rheumatoid arthritis, and multiple sclerosis. We have recently shown that these inflammatory cells play detrimental roles in the pathogenesis of both atherosclerosis and abdominal aortic aneurysm (AAA). In mice, absence or inactivation of mast cells prevents the progression of these common vascular diseases, providing the novel concept of controlling these diseases with the use of currently available generic mast cell stabilizers in humans.
Mechanistic analysis demonstrated that mast cells release proinflammatory cytokines to induce the expression and secretion of atherosclerosis-and AAA-pertinent cysteine protease cathepsins from vascular smooth muscle cells and endothelial cells. Such cysteinyl cathepsins have been suggested to participate directly in these vascular diseases mainly through their elastase and collagenase activities. Like macrophages, mast cells have reservoirs of proteases. Besides common cysteinyl cathepsins and matrix metalloproteinases, mast cells have the unique serine proteases tryptase and chymase. In this study, we proved the direct involvement of chymase in aortic elastase perfusion-induced mouse AAA. Mast cell chymases have been suggested to participate in vascular remodeling by activating matrix metalloproteinases and generating angiotensin II, critical molecules in the pathogenesis of atherosclerosis and AAA. In addition to these known pathological roles, we demonstrated in this study that mast cell chymases also control cysteinyl cathepsin expression and activation, neovascularization, and aortic smooth muscle cell apoptosis. Reduced AAA formation from mice lacking mast cell chymase and restoration of such reductions with reconstitution of mast cells from wild-type mice but not those of chymasedeficient mice strongly support a direct participation of mast cell chymases in mouse AAA formation. Observations of the AAA inhibitory effects of synthetic small-molecule orally active chymase inhibitor [2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-(3,4-dioxo-1-phenyl-7-(2-pyridyloxy)-2-heptyl)acetamide; NK3201] in several animal AAA models illustrate the possibility of controlling human AAA progression and associated complications in the near future. See p 973.
Proteomic Analysis in Aortic Media of Patients With Marfan Syndrome Reveals Increased Activity of Calpain 2 in Aortic Aneurysms
Thoracic aortic aneurysms are a life-threatening risk in patients with Marfan syndrome, bicuspid aortic valve, and severe hypertension. With progressive dilation, thoracic aneurysms may rupture and lead to severe internal bleeding and sudden death. To date, aortic aneurysms are treated with ␤-blocker therapy and surgery. Recent evidence suggests delayed dilatation of thoracic aorta in Marfan syndrome patients treated with inhibitors of the renin-angiotensin system. Neither the mechanisms leading to aneurysm formation nor the mechanisms of reduced aortic dilatation seen under treatment with antagonists of the renin-angiotensin system are as yet clearly elucidated. Proteomic technology enables large-scale screening of protein expression in tissues to be performed to unravel pathological mechanisms leading to aneurysm formation. In this study, we present the first time protein expression analysis comparing aneurysmal aorta of Marfan patients with nonaneurysmal aorta of controls. Thirteen proteins or fragments thereof were differentially expressed in aortic media of Marfan patients. Among these, a fragment of filamin A was investigated further. Analysis of proteolytic activity in aneurysmal aorta revealed increased calpain 2 activity, thus leading to fragmentation of filamin A. Similar activation of calpain 2 was found in bicuspid valve-and hypertension-associated aneurysm. Because calpain activity depends on angiotensin II levels, our findings present further evidence for the positive effect of targeting the renin-angiotensin system on aneurysm progression in Marfan syndrome. They further suggest that inhibiting the renin-angiotensin system in patients with thoracic aortic aneurysms not associated with Marfan syndrome might also be beneficial. See p 983.
